Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Busy” With Biosimilars; Sponsors Already In Pre-IND Meetings

Executive Summary

Several sponsors appear to be taking advantage of the FDA’s biosimilar pathway, even though the agency has yet to clarify how it will handle the applications.
Advertisement

Related Content

Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts
Biosimilars: Eight Is More Than Enough For FDA
Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?
Could Judges Require Independent Experts To Explain Biosimilars?
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
CMS 2012 Budget Looks To Biosimilars, Brand/Generic Deals To Offset Costs
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Waxman Says Biosimilar Pathway Will Push Applicants To BLA
Waxman Says Biosimilar Pathway Will Push Applicants To BLA

Topics

Advertisement
UsernamePublicRestriction

Register

PS053397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel